Follow
Daniel Rodrigues
Daniel Rodrigues
Verified email at icr.ac.uk
Title
Cited by
Cited by
Year
DNA-repair defects and olaparib in metastatic prostate cancer
J Mateo, S Carreira, S Sandhu, S Miranda, H Mossop, R Perez-Lopez, ...
New England Journal of Medicine 373 (18), 1697-1708, 2015
22412015
Genomic correlates of clinical outcome in advanced prostate cancer
W Abida, J Cyrta, G Heller, D Prandi, J Armenia, I Coleman, M Cieslik, ...
Proceedings of the National Academy of Sciences 116 (23), 11428-11436, 2019
9812019
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
J Mateo, N Porta, D Bianchini, U McGovern, T Elliott, R Jones, I Syndikus, ...
The Lancet Oncology 21 (1), 162-174, 2020
5462020
Tumor clone dynamics in lethal prostate cancer
S Carreira, A Romanel, J Goodall, E Grist, R Ferraldeschi, S Miranda, ...
Science translational medicine 6 (254), 254ra125-254ra125, 2014
3872014
Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition
J Goodall, J Mateo, W Yuan, H Mossop, N Porta, S Miranda, ...
Cancer discovery 7 (9), 1006-1017, 2017
3842017
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor
LJ Barber, S Sandhu, L Chen, J Campbell, I Kozarewa, K Fenwick, ...
The Journal of pathology 229 (3), 422-429, 2013
3732013
Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer
A Paschalis, B Sheehan, R Riisnaes, DN Rodrigues, B Gurel, C Bertan, ...
European urology 76 (4), 469-478, 2019
3282019
Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer
A Sharp, I Coleman, W Yuan, C Sprenger, D Dolling, DN Rodrigues, ...
The Journal of clinical investigation 129 (1), 192-208, 2019
3272019
IL-23 secreted by myeloid cells drives castration-resistant prostate cancer
A Calcinotto, C Spataro, E Zagato, D Di Mitri, V Gil, M Crespo, ...
Nature 559 (7714), 363-369, 2018
3062018
Randomized phase II study evaluating Akt blockade with ipatasertib, in combination with abiraterone, in patients with metastatic prostate cancer with and without PTEN loss
JS de Bono, U De Giorgi, DN Rodrigues, C Massard, S Bracarda, A Font, ...
Clinical Cancer Research 25 (3), 928-936, 2019
2752019
Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer
E Ruark, K Snape, P Humburg, C Loveday, I Bajrami, R Brough, ...
Nature 493 (7432), 406-410, 2013
2702013
PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate
R Ferraldeschi, DN Rodrigues, R Riisnaes, S Miranda, I Figueiredo, ...
European urology 67 (4), 795-802, 2015
2652015
Visceral disease in castration-resistant prostate cancer
CJ Pezaro, A Omlin, D Lorente, DN Rodrigues, R Ferraldeschi, ...
European urology 65 (2), 270-273, 2014
2332014
Genomics of lethal prostate cancer at diagnosis and castration resistance
J Mateo, G Seed, C Bertan, P Rescigno, D Dolling, I Figueiredo, ...
The Journal of clinical investigation 130 (4), 1743-1751, 2020
2182020
Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer
DN Rodrigues, P Rescigno, D Liu, W Yuan, S Carreira, MB Lambros, ...
The Journal of clinical investigation 128 (10), 4441-4453, 2018
2022018
Serial next-generation sequencing of circulating cell-free DNA evaluating tumor clone response to molecularly targeted drug administration
JS Frenel, S Carreira, J Goodall, D Roda, R Perez-Lopez, N Tunariu, ...
Clinical Cancer Research 21 (20), 4586-4596, 2015
2012015
Phosphorylated RB promotes cancer immunity by inhibiting NF-κB activation and PD-L1 expression
X Jin, D Ding, Y Yan, H Li, B Wang, L Ma, Z Ye, T Ma, Q Wu, ...
Molecular cell 73 (1), 22-35. e6, 2019
1962019
Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra‐tumour genetic heterogeneity and clonal …
L Hernandez, PM Wilkerson, MB Lambros, A Campion‐Flora, ...
The Journal of pathology 227 (1), 42-52, 2012
1922012
Phase I trial of first-in-class ATR inhibitor M6620 (VX-970) as monotherapy or in combination with carboplatin in patients with advanced solid tumors
TA Yap, B O’Carrigan, MS Penney, JS Lim, JS Brown, ...
Journal of Clinical Oncology 38 (27), 3195, 2020
1792020
Nrf2 as a potential mediator of cardiovascular risk in metabolic diseases
RM da Costa, D Rodrigues, CA Pereira, JF Silva, JV Alves, NS Lobato, ...
Frontiers in Pharmacology 10, 435576, 2019
1492019
The system can't perform the operation now. Try again later.
Articles 1–20